|Videos|March 30, 2022
Prognostic Value of Biomarkers in RCC
Author(s)Robert S. Alter, MD
Robert Alter, MD opines on the current prognostic value of biomarkers for RCC and the need for additional data in the field.
Advertisement
Episodes in this series
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, discusses CAR T and bispecific sequencing, fixed-duration therapy, MRD, and bispecifics in AL amyloidosis.
“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.
Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases.
Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.
Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.
In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis.
Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.
Adjuvant radiotherapy significantly reduced meningioma recurrence or death vs observation in grade 2 atypical meningioma after complete surgical resection.
Advertisement
Advertisement
Trending on CancerNetwork
1
Clinical Applications and the Future of Remote Endovascular Procedures
2
Building a Low-Dose Radiation Therapy Program for Benign Disease
3
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
4
Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer
5